Celik, EmirSuzan, VeyselSamanci, Nilay SengulSuzan, Aysegul AkkanKaradag, MehmetSahin, SerdarAslan, Muhammed Samil2024-09-182024-09-1820221878-76491878-7657https://doi.org/10.1007/s41999-021-00592-3https://hdl.handle.net/20.500.12483/12115Introduction In 2019, The EWGSOP2 group made updates on the definition and diagnosis of sarcopenia. The aim of this study is to determine the possible risk factors for chemotherapy dose-limiting toxicity (DLT). Methods Newly diagnosed gastrointestinal (GI) cancer patients were included in this prospective observational study. Chemotherapy DLTs were recorded in patients receiving platinum-based therapy. The patients were divided into two groups according to the current sarcopenia criteria. Results 75 patients were included in the final analysis. Chemotherapy DLT occurred in 52% (n = 39) of all patients who received platinum-based chemotherapy. DLT rates were 78.9% and 42.9% in sarcopenic and non-sarcopenic patients, respectively (p = 0.007). According to the results of the multivariate analysis, the only sarcopenia was found as a statistically significant risk factor for DLT. Conclusion Assessment of sarcopenia evaluated with the current EWGSOP2 diagnostic criteria is useful in predicting chemotherapy DLT development in patients with a diagnosis of GI cancer. In the future, current EWGSOP2 recommendations should be considered while designing a study investigating the correlation between sarcopenia and chemotoxicity. Key summary pointsAim To determine the possible risk factors for chemotherapy dose-limiting toxicity (DLT) in patients with gastrointestinal (GI) cancer. Findings The only sarcopenia was found as a statistically significant risk factor for chemotherapy DLT. Message Assessment of sarcopenia evaluated with the current EWGSOP2 diagnostic criteria is useful in predicting chemotherapy DLT development in GI cancer patients.eninfo:eu-repo/semantics/closedAccessSarcopeniaChemotherapy dose-limiting toxicityEWGSOP2 criteriaSarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumorsArticle13126727410.1007/s41999-021-00592-3348261112-s2.0-85119964195Q1WOS:000722807600002Q3